Correspondence 0001193125-25-223618 from REVELATION BIOSCIENCES, INC. (REVB)
REVELATION BIOSCIENCES, INC.
Date: Sept. 29, 2025 · CIK: 0001810560 · Accession: 0001193125-25-223618
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268576, 333-276232, 333-287423, 333-29039
Referenced dates: September 24, 2025
Letter
Re: Revelation Biosciences, Inc.
J.P. Galda & Co. Attorneys-at-Law 40 E Montgomery Avenue, LTW 220 Ardmore, Pennsylvania 19003 Telephone (215) 815-1534
September 30, 2025
Via EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549
Attention: Jimmy McNamara, Staff Attorney Alan Campbell, Staff Attorney
Amendment No. 1 to Registration Statement on Form S-3
Filed September 29, 2025
File No. 333-29039
Mr. McNamara and Mr. Campbell: Today Revelation Biosciences, Inc. (the “Company”) has filed Amendment No. 1 to its Registration Statement on Form S-3 to respond to the staff's letter of comments dated September 24, 2025 (the “Comment Letter”). General 1. We note that this Form S-3, among other things, constitutes a post-effective amendment to prior registration statements on Form S-1 (File Nos. 333-268576, 333-276232 and 333-287423), but you appear to have omitted the disclosure required by the form and Regulation S-K as it pertains to those offerings. Please revise the registration statement to include all of the form and Regulation S-K information that currently would be required in a prospectus relating to those offerings. Refer to Rule 429 under the Securities Act of 1933, as amended. Response: The Company has revised the Registration Statement to remove the securities that had previously been covered pursuant to Rule 429 under the Securities Act of 1933, as amended. As a result, the disclosure requirements of Rule 429 and the related provisions of Form S-3 and Regulation S-K, as they pertain to the removed securities, are no longer applicable to this prospectus.
Very truly yours,
J.P. Galda & Co.
Show Raw Text
CORRESP 1 filename1.htm CORRESP J.P. Galda & Co. Attorneys-at-Law 40 E Montgomery Avenue, LTW 220 Ardmore, Pennsylvania 19003 Telephone (215) 815-1534 September 30, 2025 Via EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Jimmy McNamara, Staff Attorney Alan Campbell, Staff Attorney Re: Revelation Biosciences, Inc. Amendment No. 1 to Registration Statement on Form S-3 Filed September 29, 2025 File No. 333-29039 Mr. McNamara and Mr. Campbell: Today Revelation Biosciences, Inc. (the “Company”) has filed Amendment No. 1 to its Registration Statement on Form S-3 to respond to the staff's letter of comments dated September 24, 2025 (the “Comment Letter”). General 1. We note that this Form S-3, among other things, constitutes a post-effective amendment to prior registration statements on Form S-1 (File Nos. 333-268576, 333-276232 and 333-287423), but you appear to have omitted the disclosure required by the form and Regulation S-K as it pertains to those offerings. Please revise the registration statement to include all of the form and Regulation S-K information that currently would be required in a prospectus relating to those offerings. Refer to Rule 429 under the Securities Act of 1933, as amended. Response: The Company has revised the Registration Statement to remove the securities that had previously been covered pursuant to Rule 429 under the Securities Act of 1933, as amended. As a result, the disclosure requirements of Rule 429 and the related provisions of Form S-3 and Regulation S-K, as they pertain to the removed securities, are no longer applicable to this prospectus. Very truly yours, J.P. Galda & Co. /s/ J.P. Galda & Co.